E-LIB Suche - Ergebnisse für: Thomalla, D.

1

Documentation of other research data and databases used:

Hilgetag, Claus ; Büchel, Christine ; Ritter, Petra...
doi:10.25592/uhhfdm.13400. , 2023

Link: https://doi.org/10.25592..

2

Deregulation and epigenetic modification of BCL2-family gen..:

Thomalla, D ; Beckmann, L ; Grimm, C...
http://edoc.mdc-berlin.de/21709/1/21709oa.pdf. , 2022

Link: http://edoc.mdc-berlin.d..

3

Curricular course for medical students at a hematology and ..:

Weide, R ; Thomalla, J ; van Roye, C...
Barrows HS, Tamblyn RM. Problem-based learning: An approach to medical education. New York: Springer Publishing Company; 1980.. , 2022

Link: https://doi.org/10.3205/..

4

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASON..:

Mai, E. K ; Bertsch, U ; Fenk, R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429267/. , 2022

Link: http://www.ncbi.nlm.nih...

5

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASON..:

E. K. Mai ; U. Bertsch ; R. Fenk...
http://journals.lww.com/10.1097/01.HS9.0000846588.94000.04. , 2022

Link: https://doi.org/10.1097/..

6

Assessment of imatinib as first-line treatment of chronic m..:

Hehlmann, R ; Lauseker, M ; Saußele, S...
1476-5551. , 2019

Link: https://resolver.sub.uni..

7

Clonal dynamics towards the development of venetoclax resis..:

Herling, C.D ; Abedpour, N ; Weiss, J...
http://edoc.mdc-berlin.de/20598/1/20598oa.pdf. , 2018

Link: http://edoc.mdc-berlin.d..

8

Survival of patients with advanced solid tumours who are tr..:

Weide, R ; Chakupurakal, G ; Feiten, S...
http://dx.doi.org/10.3205/18dkvf005. , 2018

Link: https://doi.org/10.3205/..

9

Socio-economic benefits of weather and climate services in ..:

Perrels, A ; Frei, Th ; Espejo, F..
doi:10.5194/asr-10-65-2013. , 2018

Link: https://doi.org/10.5194/..

10

Assessment of imatinib as first-line treatment of chronic m..:

Hehlmann, R ; Lauseker, M ; Saußele, S...
http://edoc.mdc-berlin.de/16712/1/16712oa.pdf. , 2017

Link: http://edoc.mdc-berlin.d..

11

Assessment of imatinib as first-line treatment of chronic m..:

Hehlmann, R ; Lauseker, M ; Saußele, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668495/. , 2017

Link: http://www.ncbi.nlm.nih...

12

Assessment of imatinib as first-line treatment of chronic m..:

Hehlmann, R ; Lauseker, M ; Baerlocher, G. M...
info:eu-repo/semantics/altIdentifier/issn/0887-6924. , 2017

Link: https://publications.rwt..

13

Die Versorgungsrealität von Patienten mit Multiplem Myelom ..:

Weide, R ; Feiten, S ; Chakupurakal, G...
http://dx.doi.org/10.3205/17dkvf385. , 2017

Link: https://doi.org/10.3205/..

14

Assessment of imatinib as first-line treatment of chronic m..:

Hehlmann, R ; Lauseker, M ; Saußele, S...
https://boris.unibe.ch/110090/. , 2017

Link: https://boris.unibe.ch/1..

15

Follow-up Reality for Breast Cancer Patients – Standardised..:

Feiten, S ; Dünnebacke, J ; Friesenhahn, V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873294/. , 2016

Link: http://www.ncbi.nlm.nih...